

Integrum comments on OsteoCentric's announcement of outcome in the public offer

Mölndal, Sweden, September 17th, 2025 - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) comments on OsteoCentric's announcement of outcome in the public offer.

September 16, 2025 at 07:00 CEST, OsteoCentric announced that approximately 69.4 percent of the shares in Integrum had been tendered and that the offer will not be completed as the 90 percent acceptance condition was not satisfied. Integrum disagrees with OsteoCentric's conclusion that the acceptance condition was not satisfied and wishes to further clarify its position on this matter.

As previously announced in connection with the public offer, Integrum's founder and largest shareholder, Rickard Brånemark, entered into an irrevocable undertaking to accept OsteoCentric's offer for all of his A and B shares. On 9 September 2025, Rickard Brånemark, who directly and indirectly held approximately 28 percent of the shares in Integrum, submitted duly signed and otherwise complete acceptance forms to Avanza, the receiving agent appointed by the offeror, for all of his A and B shares. Avanza has informed our legal advisors that Avanza attempted to transfer these shares to a blocked securities account (Sw. apportkonto), but has stated that this could not be completed due to a technical blockage. The nature and cause of this blockage have not yet been clarified and is still investigated.

According to the terms and instructions of the offer, directly registered shareholders accept the offer by submitting a duly signed acceptance form to Avanza. In this case, the offeror has not disputed that such forms were submitted by the main shareholder.

Integrum is currently considering referring to the Swedish Securities Council (Aktiemarknadsnämnden) the questions of whether the acceptance condition has been satisfied and whether the offeror has fulfilled its obligation under the Takeover Rules to endeavour to ensure that stipulated conditions are met. If Rickard Brånemark's shares had been included in the acceptance tally, the total acceptance level in the offer would have amounted to approximately 97.6 percent of all shares in Integrum. This means that the 90 percent acceptance condition would have been fulfilled. Integrum's view is that further engagement by the offeror with the main shareholder could have resolved any technical blockage in the Euroclear Sweden (VPC) system.

Integrum will continue to investigate the circumstances relating to the satisfaction of the completion condition and will provide further updates to the market as new information becomes available.

Please note that the outcome of any review, including by the Swedish Securities Council, remains uncertain. Even if a favorable decision is obtained, there can be no guarantee that the offer will be completed or completed as set out in the offer document.

Integrum AB
The Board of Directors

This information is information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on 17 September 2025 at 00:30 CEST.

For more information, please contact:

Kristofer Westergren, Board member and Chair of the independent bid committee

E-mail: kristofer@kcap.se

Tel: +46 (0)31 760 10 60

Certified Adviser

The Company's Certified Adviser is DNB Carnegie Investment Bank AB.

About Integrum

Integrum is a publicly traded company (Nasdaq First North Growth Market: INTEG B) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA® Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA® Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit <https://integrum.se/>.